13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
41 檔
26.1%
At the close of Q3 2024, Octagon Capital Advisors LP disclosed equity holdings valued at approximately $1.1B, spread across 41 reported holdings.
In Q3 2024, Octagon Capital Advisors LP adopted a defensive or profit-taking posture, trimming 10 positions and completely liquidating 10 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 13.49% | — | -6.93% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 8.21% | — | -3.17% | |
| 3 | GPCR | Structure Therapeutics Inc | Stock-Other | 8.18% | — | +5.08% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 7.80% | — | -23.70% | |
| 5 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.44% | -1.94% | — | |
| 6 | AVBP | Arrivent Biopharma Inc | Stock-Other | 7.22% | +1.12% | +9.60% | |
| 7 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 5.00% | -3.30% | EXIT | |
| 8 | NUVB | Nuvation Bio Inc | Stock-Other | 4.34% | — | +2720.09% | |
| 9 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 3.58% | — | +128.48% | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.28% | -1.14% | — | |
| 11 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.08% | — | +40.32% | |
| 12 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.95% | -0.37% | EXIT | |
| 13 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.67% | — | +40.18% | |
| 14 | COGT | Cogent Biosciences Inc | Stock-Other | 2.19% | -1.84% | — | |
| 15 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 2.19% | — | -20.00% | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 1.79% | +0.90% | — | |
| 17 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.47% | — | -77.75% | |
| 18 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 1.43% | +1.55% | — | |
| 19 | GOSS | Gossamer Bio Inc | Stock-Other | 1.41% | -0.17% | — | |
| 20 | ✓ | Stock-Other | 1.41% | — | +14.31% | ||
| 21 | EYPT | Eyepoint Inc | Stock-Other | 1.36% | — | — | |
| 22 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.16% | — | -50.00% | |
| 23 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.13% | — | — | |
| 24 | RGLS | Regulus Therapeutics Inc | Stock-Other | 1.04% | — | — | |
| 25 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.81% | — | — | |
| 26 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.77% | — | — | |
| 27 | HELP | Cybin Inc | Stock-Other | 0.68% | — | — | |
| 28 | ✓ | Reneo Pharmaceuticals Inc | Stock-Other | 0.59% | — | — | |
| 29 | ✓ | Stock-Other | 0.54% | — | — | ||
| 30 | PEPG | Pepgen Inc | Stock-Other | 0.50% | — | — | |
| 31 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.41% | — | — | |
| 32 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.40% | — | — | |
| 33 | ANNX | Annexon Inc | Stock-Other | 0.37% | — | — | |
| 34 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.29% | — | — | |
| 35 | IPSC | Century Therapeutics Inc | Stock-Other | 0.18% | — | -50.00% | |
| 36 | ✓ | Stock-Other | 0.15% | — | — | ||
| 37 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.11% | — | — | |
| 38 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.10% | — | — | |
| 39 | NGNE | Neurogene Inc | Stock-Other | 0.10% | — | — | |
| 40 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.09% | — | — | |
| 41 | NKTX | Nkarta Inc | Stock-Other | 0.08% | — | -50.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NUVB | Nuvation Bio Inc | +4.1% | +2720.09% | Add |
| 2 | VRNA | Verona Pharma PLC - Adr | +3.9% | -3.17% | Trim |
| 3 | COGT | Cogent Biosciences Inc | +2.2% | NEW | New buy |
| 4 | AVBP | Arrivent Biopharma Inc | +2% | +9.60% | Add |
| 5 | VRDN | Viridian Therapeutics Inc | +1.8% | +40.32% | Add |
| 6 | PHVS | Pharvaris N.V. | +1.8% | NEW | New buy |
| 7 | 260 | Centessa Pharmaceuticals-adr | +1.7% | -14.20% | Trim |
| 8 | GPCR | Structure Therapeutics Inc | +1.1% | +5.08% | Add |
| 9 | HELP | Cybin Inc | +0.7% | NEW | New buy |
| 10 | OCUL | Ocular Therapeutix Inc | +0.7% | — | Unchanged |
| 11 | ✓ | +0.5% | NEW | New buy | |
| 12 | CATX | Perspective Therapeutics Inc | +0.5% | -10.00% | Trim |
| 13 | BDTX | Black Diamond Therapeutics I | +0.4% | NEW | New buy |
| 14 | DNTH | Dianthus Therapeutics Inc | +0.3% | — | Unchanged |
| 15 | ✓ | +0.3% | +14.31% | Add | |
| 16 | BRD1EUR | Mind Medicine Mindmed Inc | +0.2% | +40.18% | Add |
| 17 | CRBP | Corbus Pharmaceuticals Holdi | +0.1% | +128.48% | Add |
| 18 | GOSS | Gossamer Bio Inc | +0.1% | — | Unchanged |
| 19 | NUVB-WS | Nuvation Bio Inc -cw27 | +0.1% | NEW | New buy |
| 20 | NGNE | Neurogene Inc | +0.1% | NEW | New buy |
| 21 | ✓ | Reneo Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 22 | ANNX | Annexon Inc | +0.1% | — | Unchanged |
| 23 | MLYS | Mineralys Therapeutics Inc | 0% | — | Unchanged |
| 24 | ✓ | 0% | — | Unchanged | |
| 25 | ✓ | Helix Acquisition CORP Ii | 0% | — | Unchanged |
| 26 | AUTL | Autolus Therapeutics PLC | — | — | Unchanged |
| 27 | ✓ | Mersana Therapeutics Inc | 0% | — | Unchanged |
| 28 | ✓ | Rapt Therapeutics Inc | -0.1% | — | Unchanged |
| 29 | VTYXUSD | Ventyx Biosciences Inc | -0.1% | — | Unchanged |
| 30 | NKTX | Nkarta Inc | -0.1% | -50.00% | Trim |
| 31 | EYPT | Eyepoint Inc | -0.1% | — | Unchanged |
| 32 | TORCEUR | Adicet Bio Inc | -0.2% | EXIT | Sold out |
| 33 | RGLS | Regulus Therapeutics Inc | -0.2% | — | Unchanged |
| 34 | TSHA | Taysha Gene Therapies Inc | -0.2% | — | Unchanged |
| 35 | FATE | Fate Therapeutics Inc | -0.3% | EXIT | Sold out |
| 36 | ✓ | Elevation Oncology Inc | -0.3% | EXIT | Sold out |
| 37 | PSTXUSD | Poseida Therapeutics Inc | -0.3% | EXIT | Sold out |
| 38 | IPSC | Century Therapeutics Inc | -0.4% | -50.00% | Trim |
| 39 | PEPG | Pepgen Inc | -0.4% | — | Unchanged |
| 40 | TNYA | Tenaya Therapeutics Inc | -0.5% | — | Unchanged |
| 41 | SLN | Silence Therapeutics Plc-adr | -0.5% | EXIT | Sold out |
| 42 | PRAX | Praxis Precision Medicines I | -0.5% | -50.00% | Trim |
| 43 | BBIO | Bridgebio Pharma Inc | -0.6% | -20.00% | Trim |
| 44 | CYBNEUR | Cybin Inc | -0.8% | EXIT | Sold out |
| 45 | JSPR | Jasper Therapeutics Inc | -1% | EXIT | Sold out |
| 46 | AKRO | Akero Therapeutics Inc | -1% | EXIT | Sold out |
| 47 | ANTX | An2 Therapeutics Inc | -1.1% | EXIT | Sold out |
| 48 | 430 | Terns Pharmaceuticals Inc | -1.5% | EXIT | Sold out |
| 49 | INSM | Insmed Inc | -1.7% | -23.70% | Trim |
| 50 | DYN | Dyne Therapeutics Inc | -5.1% | -77.75% | Trim |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 41 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including APLSUSD, VRNA, GPCR) accounted for 26.1% of total reported equity market value during Q3 2024.
Top New Position Initiated
COGT
市值: $14.1M
Top Position Liquidated / Trimmed
430
前期市值: $9.3M
During Q3 2024, Octagon Capital Advisors LP's top holdings by market value included APLSUSD (13.5%)、VRNA (8.2%)、GPCR (8.2%). The largest single position, APLSUSD, represented 13.5% of total portfolio value.
In Q3 2024, Octagon Capital Advisors LP made 34 total portfolio adjustments, initiating 7 new buys, adding to 7 positions, trimming 10 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.